Ikaria Australia

Ikaria Australia is a specialty pharmaceutical and medical technology company dedicated to the critical care market, specifically focusing on neonatal and pediatric intensive care. The company's flagship product is INOmax (nitric oxide) for inhalation, a vasodilator used to treat term and near-term infants with hypoxic respiratory failure. Beyond the therapeutic gas, Ikaria provides the specialized delivery systems and 24/7 technical support necessary for its administration in high-stakes hospital environments. In 2015, the global Ikaria organization was acquired by Mallinckrodt Pharmaceuticals for approximately $2.3 billion. Today, Ikaria Australia operates as a key subsidiary of Mallinckrodt, managing the commercial footprint and clinical support for critical care therapies across Australia and New Zealand.